KR102412212B1 - 황-함유 화합물을 포함하는 마이크로입자 - Google Patents

황-함유 화합물을 포함하는 마이크로입자 Download PDF

Info

Publication number
KR102412212B1
KR102412212B1 KR1020187035476A KR20187035476A KR102412212B1 KR 102412212 B1 KR102412212 B1 KR 102412212B1 KR 1020187035476 A KR1020187035476 A KR 1020187035476A KR 20187035476 A KR20187035476 A KR 20187035476A KR 102412212 B1 KR102412212 B1 KR 102412212B1
Authority
KR
South Korea
Prior art keywords
microparticle
microparticles
cysteamine
pharmaceutical composition
ethylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187035476A
Other languages
English (en)
Korean (ko)
Other versions
KR20190016957A (ko
Inventor
데보라 오닐
Original Assignee
노바바이오틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바바이오틱스 리미티드 filed Critical 노바바이오틱스 리미티드
Publication of KR20190016957A publication Critical patent/KR20190016957A/ko
Application granted granted Critical
Publication of KR102412212B1 publication Critical patent/KR102412212B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Accessories For Mixers (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020187035476A 2016-06-07 2017-06-06 황-함유 화합물을 포함하는 마이크로입자 Active KR102412212B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
US62/346,969 2016-06-07
GB1609940.0 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Publications (2)

Publication Number Publication Date
KR20190016957A KR20190016957A (ko) 2019-02-19
KR102412212B1 true KR102412212B1 (ko) 2022-06-23

Family

ID=56508202

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187035476A Active KR102412212B1 (ko) 2016-06-07 2017-06-06 황-함유 화합물을 포함하는 마이크로입자

Country Status (16)

Country Link
US (1) US11369568B2 (enExample)
EP (1) EP3463325B1 (enExample)
JP (1) JP7195934B2 (enExample)
KR (1) KR102412212B1 (enExample)
CN (1) CN109310654A (enExample)
AU (1) AU2017277897B2 (enExample)
BR (1) BR112018075221B1 (enExample)
CA (2) CA3026743C (enExample)
DK (1) DK3463325T3 (enExample)
ES (1) ES2965017T3 (enExample)
FI (1) FI3463325T3 (enExample)
GB (1) GB201609940D0 (enExample)
MX (1) MX2018014278A (enExample)
SG (1) SG11201810934TA (enExample)
WO (1) WO2017212249A1 (enExample)
ZA (1) ZA201807852B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
ES3024695T3 (en) * 2018-10-17 2025-06-05 Novabiotics Ltd Cysteamine for use in the treatment of lung diseases
JP2023540985A (ja) * 2020-09-03 2023-09-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 噴霧乾燥低吸湿性活性粉末組成物
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
CN118871100A (zh) * 2021-12-07 2024-10-29 西拉治疗公司 抗病毒治疗剂及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054574A1 (en) * 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8901570D0 (sv) 1989-05-02 1989-05-02 Draco Ab Organic salts of cysteine derivatives
CN101094651B (zh) * 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
AU2007338210B2 (en) 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
WO2010060875A1 (de) 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Neue pulverförmige kristalline arzneimittel zur inhalation
AU2010210620B2 (en) * 2009-02-03 2016-02-25 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
WO2010138419A2 (en) 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
JP6012716B2 (ja) 2011-05-19 2016-10-25 サヴァラ，インク． 乾燥粉末バンコマイシン組成物および関連する方法
JP5981123B2 (ja) * 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク ニコチン薬の製造法およびその方法により製造される医薬
BR112014009789A2 (pt) * 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
US9493775B2 (en) * 2012-02-10 2016-11-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
ITMI20130572A1 (it) 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
GB201416716D0 (en) 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054574A1 (en) * 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B. Buchan, FORMULATION STUDIES ON CYSTEAMINE FOR THE TREATMENT OF NEPHROPATHIC CYSTINOSIS, Robert Gordon University, 2011, pp. 1-223

Also Published As

Publication number Publication date
MX2018014278A (es) 2019-03-14
US11369568B2 (en) 2022-06-28
CA3026743C (en) 2024-05-28
RU2018142841A (ru) 2020-06-04
BR112018075221A2 (pt) 2019-03-19
AU2017277897B2 (en) 2022-09-08
CA3026743A1 (en) 2017-12-14
ZA201807852B (en) 2023-05-31
ES2965017T3 (es) 2024-04-10
KR20190016957A (ko) 2019-02-19
EP3463325B1 (en) 2023-11-08
JP2019517541A (ja) 2019-06-24
EP3463325A1 (en) 2019-04-10
SG11201810934TA (en) 2019-01-30
AU2017277897A1 (en) 2018-12-20
US20190175501A1 (en) 2019-06-13
GB201609940D0 (en) 2016-07-20
BR112018075221B1 (pt) 2024-02-06
DK3463325T3 (da) 2024-01-02
FI3463325T3 (fi) 2023-12-19
NZ748596A (en) 2025-06-27
CA3096121C (en) 2022-11-15
WO2017212249A1 (en) 2017-12-14
CA3096121A1 (en) 2017-12-14
CN109310654A (zh) 2019-02-05
JP7195934B2 (ja) 2022-12-26
RU2018142841A3 (enExample) 2020-09-30

Similar Documents

Publication Publication Date Title
KR102412212B1 (ko) 황-함유 화합물을 포함하는 마이크로입자
US10905660B2 (en) Microparticles
CA2468958C (en) Pulmonary delivery of aminoglycosides
CA2981038C (en) Dry powder vancomycin compositions and associated methods
BR112013007304B1 (pt) Pós secos de cátion de metal monovalente para inalação
Manniello et al. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility
JP2012522009A (ja) 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
CN102448439A (zh) 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
US10561608B2 (en) Dry powder Vancomycin compositions and associated methods
PT1594500E (pt) Tratamento para doenças bacterianas dos órgãos respiratórios por aplicação local de fluoroquinolonas
RU2780397C2 (ru) Микрочастицы, содержащие серосодержащие соединения
Saha et al. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections
ES2918193T3 (es) Polvo medicamentoso para administración por inhalación y un proceso del mismo
WO2006033713A2 (en) Methods for ciprofloxacin inhalation
IL263540B2 (en) Microparticles that include a sulfur-containing compound
AU2002361897B2 (en) Pulmonary delivery of aminoglycosides

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181206

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200604

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210924

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220310

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210924

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220310

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20211123

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200604

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190115

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220420

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220411

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220310

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20211123

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200604

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190115

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220620

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220621

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250609

Start annual number: 4

End annual number: 4